Inhibition of Btk with CC-292 Provides Early Pharmacodynamic Assessment of Activity in Mice and Humans - Evans, Erica K.; Tester, Richland; Aslanian, Sharon; Karp, Russell; Sheets, Michael; Labenski, Matthew T.; Witowski, Steven R.; Lounsbury, Heather; Chaturvedi, Prasoon; Mazdiyasni, Hormoz; Zhu, Zhendong; Nacht, Mariana; et al. (The Journal of pharmacology and experimental therapeutics, 2013)
Keywords: Acrylamides - pharmacokinetics; Acrylamides - pharmacology; Acrylamides - therapeutic use; Agammaglobulinaemia Tyrosine Kinase; Animals; Arthritis, Experimental - drug therapy; Arthritis, Experimental - immunology; Arthritis, Rheumatoid - drug therapy; Arthritis, Rheumatoid - immunology; B-Lymphocytes - drug effects; B-Lymphocytes - metabolism; Double-Blind Method; Humans; Mice; Protein-Tyrosine Kinases - antagonists & inhibitors; Pyrimidines - pharmacokinetics; Pyrimidines - pharmacology; Pyrimidines - therapeutic use; Receptors, Antigen, B-Cell - metabolism; Signal Transduction; PBS; CLL; CC-292; CST; PLC; XLA; BCR; BSA; PD; Btk; CIA; PK; CNX-500; ELISA